Biogen Idec Pays $20M To Settle Patent Suit With Corixa, GSK
Biogen Idec agreed to pay $20 million to settle its outstanding patent litigation with rival Corixa and its marketing partner, GlaxoSmithKline, over patents for a cancer drug, the companies said Monday....To view the full article, register now.
Already a subscriber? Click here to view full article